Neuronetics (STIM) Competitors $3.40 +0.02 (+0.59%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.42 +0.02 (+0.59%) As of 08/22/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STIM vs. KMTS, EMBC, BBNX, TNDM, AXGN, SIBN, BVS, ZIMV, AVNS, and SMLRShould you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include Kestra Medical Technologies (KMTS), Embecta (EMBC), Beta Bionics (BBNX), Tandem Diabetes Care (TNDM), AxoGen (AXGN), SiBone (SIBN), Bioventus (BVS), ZimVie (ZIMV), AVANOS MEDICAL (AVNS), and Semler Scientific (SMLR). These companies are all part of the "medical equipment" industry. Neuronetics vs. Its Competitors Kestra Medical Technologies Embecta Beta Bionics Tandem Diabetes Care AxoGen SiBone Bioventus ZimVie AVANOS MEDICAL Semler Scientific Kestra Medical Technologies (NASDAQ:KMTS) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations. Is KMTS or STIM more profitable? Kestra Medical Technologies has a net margin of 0.00% compared to Neuronetics' net margin of -43.47%. Kestra Medical Technologies' return on equity of 0.00% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Kestra Medical TechnologiesN/A N/A N/A Neuronetics -43.47%-156.36%-35.69% Do analysts rate KMTS or STIM? Kestra Medical Technologies currently has a consensus price target of $27.33, suggesting a potential upside of 47.11%. Neuronetics has a consensus price target of $7.00, suggesting a potential upside of 105.88%. Given Neuronetics' stronger consensus rating and higher probable upside, analysts plainly believe Neuronetics is more favorable than Kestra Medical Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kestra Medical Technologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Neuronetics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of KMTS or STIM? 53.6% of Neuronetics shares are held by institutional investors. 3.6% of Kestra Medical Technologies shares are held by insiders. Comparatively, 8.7% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer KMTS or STIM? In the previous week, Neuronetics' average media sentiment score of 1.79 beat Kestra Medical Technologies' score of 0.00 indicating that Neuronetics is being referred to more favorably in the news media. Company Overall Sentiment Kestra Medical Technologies Neutral Neuronetics Very Positive Which has higher valuation & earnings, KMTS or STIM? Neuronetics has higher revenue and earnings than Kestra Medical Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKestra Medical Technologies$59.81M15.95-$113.81MN/AN/ANeuronetics$74.89M3.00-$43.71M-$1.13-3.01 SummaryNeuronetics beats Kestra Medical Technologies on 7 of the 12 factors compared between the two stocks. Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STIM vs. The Competition Export to ExcelMetricNeuroneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$223.50M$6.82B$5.75B$9.62BDividend YieldN/A1.31%4.40%4.10%P/E Ratio-3.0127.4531.3026.05Price / Sales3.0074.72432.98193.75Price / CashN/A21.3437.7358.48Price / Book7.086.889.536.61Net Income-$43.71M$176.42M$3.26B$265.65M7 Day Performance1.80%1.45%2.13%2.02%1 Month Performance-23.42%-2.71%2.80%-0.31%1 Year Performance252.33%9.40%30.68%19.06% Neuronetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STIMNeuronetics2.3338 of 5 stars$3.40+0.6%$7.00+105.9%+249.0%$223.50M$74.89M-3.01180Positive NewsKMTSKestra Medical TechnologiesN/A$16.09+0.2%$27.33+69.9%N/A$824.15M$59.81M0.00300News CoverageEMBCEmbecta4.8379 of 5 stars$13.48-1.5%$19.00+40.9%+9.0%$800.66M$1.12B9.432,100Positive NewsBBNXBeta Bionics2.6051 of 5 stars$17.26+1.3%$22.56+30.7%N/A$740.73M$65.12M0.00294News CoverageInsider TradeTNDMTandem Diabetes Care4.6554 of 5 stars$10.84+0.2%$22.67+109.1%-71.9%$731.10M$940.20M-3.512,650Positive NewsAnalyst ForecastAXGNAxoGen2.7505 of 5 stars$15.49+3.8%$26.00+67.9%+31.7%$686.97M$203.27M-154.88450Short Interest ↑SIBNSiBone4.1725 of 5 stars$15.54+0.5%$23.67+52.3%+10.0%$666.96M$167.18M-27.75350News CoverageInsider TradeBVSBioventus0.98 of 5 stars$7.18-2.6%N/AN/A$609.34M$573.28M14.741,200ZIMVZimVie0.6943 of 5 stars$18.95+0.5%$17.75-6.3%+11.2%$531.59M$449.75M-27.071,770Positive NewsShort Interest ↑AVNSAVANOS MEDICAL3.2808 of 5 stars$11.24+0.4%N/A-49.6%$519.71M$687.80M-1.122,227Positive NewsShort Interest ↑SMLRSemler Scientific3.4737 of 5 stars$33.76-0.2%$81.75+142.2%+11.0%$500.99M$56.29M13.89120Positive News Related Companies and Tools Related Companies KMTS Competitors EMBC Competitors BBNX Competitors TNDM Competitors AXGN Competitors SIBN Competitors BVS Competitors ZIMV Competitors AVNS Competitors SMLR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STIM) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access